Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026

Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) shares fell 4.5% during mid-day trading

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Wei

Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with

JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a

Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc

BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, fundin

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutica

BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the se

Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as t

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's str

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Ove

Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and rais

Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p

Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lo

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and

Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: EL

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the a

Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001  ef

Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 1

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a

Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p

Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and ra

This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gain

Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction

BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded War

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previo

US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus

Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%.

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ: ELVN), a clinical-stage biopharmaceutic

61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR

Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad

Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rati

Enliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achievin

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and